Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis.
Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis.
Inclusion Criteria:
Patient hospitalised with ischemic symptoms (onset < 48 hours) and at least one of the following characteristics of NSTEMI:
Patient treated on admission with 250-500 mg aspirin (oral or IV) and who will receive low dose aspirin (< or = 100 mg daily) from the next day on
Patient treated with bid LMWH (indicated dosage for this indication)
Exclusion Criteria:
Catheterization scheduled within 24 hours after randomisation
Patient presenting an absolute contra-indication to the use of clopidogrel and/or ASA:
- history of drug allergy to thienopyridine derivatives or ASA
Severe uncontrolled hypertension (BP > 180 / 100 despite therapy)
Platelet count < 100 000 / mm3
Neutrophil count < 1800 / mm3
Patient with increased risk of bleeding, such as severe hepatic insufficiency, current peptic ulceration, proliferative diabetic retinopathy
History of severe systemic bleeding
Patient with any contraindication to LMWH
Patient treated with clopidogrel within the last 10 days
Patient treated with oral anticoagulants or hirudin or planned to receive these products during the hospitalisation period
Patient treated with ticlopidine, dipyridamol, NSAIDs (including Cox1 and Cox2 inhibitors), cilostazol, GPIIb IIIa antagonists or planned to receive any of these products within the next 24 hours following randomisation.
Patient whose arm venous status is incompatible with an indwelling catheter
Patient presenting an evolving cancer
Patient with NYHA class IV heart failure
Intubated and ventilated patient